[This Week's IPO] February Fourth Week Demand Forecast and Subscription Schedule

In the fourth week of this month (February), Osang Healthcare and D&D Pharmatech will conduct demand forecasting targeting institutional investors.

◆Osang Healthcare= Established in 1996, Osang Healthcare is a specialized company in the field of in vitro diagnostics, including biochemical diagnostics, molecular diagnostics, and immunodiagnostics. In 1997, it developed the first fully automated biochemical analyzer for blood tests used in hospitals in Korea, and in 2003, it became the first in the country to obtain FDA approval in the United States for a personal blood glucose meter, demonstrating its technological capabilities in the biochemical diagnostics field.

In this IPO, it plans to offer 990,000 shares with a desired public offering price of 13,000 to 15,000 KRW per share. The offering size is estimated to be between 12.9 billion and 14.9 billion KRW. Demand forecasting will be conducted over five days from the 21st to the 27th targeting domestic and foreign institutional investors, and general subscription will be held over two days on March 4th and 5th. The lead underwriter is NH Investment & Securities.

◆D&D Pharmatech= Founded in 2014, D&D Pharmatech is a company specializing in the development of chronic disease treatments using GLP-1 peptide-based drugs. The company is developing multiple GLP-1 based new drugs, including ▲oral obesity treatments ▲injectable NASH treatment (DD01) ▲degenerative brain disease treatment (NLY01).

In this IPO, it plans to offer 1,100,000 shares with a desired public offering price of 22,000 to 26,000 KRW per share. The offering size is estimated to be between 24.2 billion and 28.6 billion KRW. Demand forecasting will be conducted over five days from the 22nd to the 28th targeting domestic and foreign institutional investors, and general subscription will be held over two days on March 6th and 7th. The lead underwriter is Korea Investment & Securities.

This content was produced with the assistance of AI translation services.